John F. Paolini - Mar 16, 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Mar 16, 2025
Transactions value $
-$11,463
Form type
4
Date filed
3/19/2025, 05:48 PM
Previous filing
Sep 4, 2024
Next filing
Apr 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +1.73K +3.31% 53.8K Mar 16, 2025 Direct F1
transaction KNSA Class A Ordinary Share Tax liability -$11.5K -507 -0.94% $22.61 53.3K Mar 16, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -1.73K -100% $0.00 0 Mar 16, 2025 Class A Ordinary Share 1.73K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.